Skip to main content

Marte Schrumpf Heiberg

Seniorforsker
https://orcid.org/0000-0003-1104-7755
Se Google Scholar profil
Se publikasjoner i PubMed

Utdanning

  • Lege (MD), Universitet i Oslo (2001)
  • Spesialist i revmatologi (2015)
  • Doktorgrad (PhD) ved Institutt for klinisk medisin, Universitetet i Oslo (2009)

Stilling

  • Seniorforsker, Klinikk for revmatologi, poliklinikk og forskning, Diakonhjemmet sykehus
  • Overlege i revmatologi, Klinikk for revmatologi, poliklinikk og forskning, Diakonhjemmet sykehus

Interessefelt

  • Revmatologi
  • Artrittsykdommer
  • Immunterapi
  • Anti-revmatiske sykdomsmodifiserende legemidler

Annet

  • Leder for Nasjonalt klinisk nettverk i REMEDY

E-post

Denne e-postadressen er beskyttet mot programmer som samler e-postadresser. Du må aktivere javaskript for å kunne se den.

Telefon

Besøksadresse

Diakonhjemmet sykehus
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postadresse

Diakohjemmet sykehus
Postboks 23 Vinderen
0319 Oslo

Prosjekter

WP1 - Behandlingsstudier

NORD-STAR

Den nordiske studien av strategiprøver og registre for revmatiske sykdommer

Prosjektleder:
Espen A. Haavardsholm
WP2 - Presisjonsmedisin

RIMRA

Revmatiske immunrelaterte bivirkninger hos pasienter behandlet med immunterapi

Prosjektleder:
Marte Schrumpf Heiberg
WP2 - Presisjonsmedisin

START

Stratifisering av akutt inflammatorisk artritt

Prosjektleder:
Silje Watterdal Syversen

Publikasjoner

Publikasjoner hentet fra Nasjonalt vitenarkiv (NVA):

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study

Violetta Dubovyk, Georgios K. Vasileiadis, Tahzeeb Fatima, Yuan Zhang, Meliha Crnkic Kapetanovic, Alf Kastbom


RMD Open

2024

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

Kristina Lend, Jon Lampa, Leonid Padyukov, Merete Lund Hetland, Marte Schrumpf, Dan C Nordström


Annals of the Rheumatic Diseases

2024

Circulating Baseline CXCR3+Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis

Julia M. Scheffler, Christina Drevinge, Catharina Lindholm, Inger Gjertsson, Kristina Lend, Merete Lund Hetland


ACR Open Rheumatology

2024

Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial

Kristina Lend, Frieda A. Koopman, Jon Lampa, Gerrit Jansen, Merete L. Hetland, Till Uhlig


Arthritis & Rheumatology

2023

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Mikkel Østergaard, Ronald F Van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf, Dan C Nordström


Annals of the Rheumatic Diseases

2023

Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial

Kristina Lend, Ronald F van Vollenhoven, Jon Lampa, Merete Lund Hetland, Espen A. Haavardsholm, Dan Nordström


The Lancet Rheumatology

2022

Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis

Jonathan Aldridge, Anna-Carin Lundell, Kerstin Andersson, Linda Mark, Merete Lund Hetland, Mikkel Østergaard


Clinical and Experimental Rheumatology

2021

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.

Marit Stockfelt, Anna-Carin Lundell, Merete Lund Hetland, Mikkel Østergaard, Till Uhlig, Marte Schrumpf


Arthritis Research & Therapy

2021

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial

Merete Lund Hetland, Espen A. Haavardsholm, Anna Rudin, Dan C. Nordström, Michael Nurmohamed, Bjorn Gudbjornsson


The BMJ

2020

Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International Immunocancer Registry (ICIR)

Manuel Ramos-Casals, Alexandre Maria, María E. Suarez-Almazor, Olivier Lambotte, Benjamin A. Fisher, Gabriela Hernández-Molina


Clinical and Experimental Rheumatology

2019

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: Study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study

Daniel Glinatsi, Marte Schrumpf, Anna Rudin, Dan C. Nordström, Espen A. Haavardsholm, Björn Gudbjörnsson


Trials

2017

Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study

Karen Minde Fagerli, Desirée van der Heijde, Marte Schrumpf Heiberg, Ada Wierød, Synnøve Kalstad, Erik Rødevand


Rheumatology

2014

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study

Karen Minde Fagerli, Elisabeth Lie, Desirée van der Heijde, Marte S. Heiberg, Åse Lexberg, Erik Rødevand


Annals of the Rheumatic Diseases

2014

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study

Karen Minde Fagerli, Elisabeth Lie, Desirée van der Heijde, Marte Schrumpf, Synnøve Kalstad, Erik Rødevand


Annals of the Rheumatic Diseases

2013

Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria

Karen Minde Fagerli, Elisabeth Lie, Desirée van der Heijde, Marte Schrumpf, Cecilie Kaufmann, Erik Rødevand


Rheumatology

2012

Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis

Elisabeth Lie, Désirée Van der heijde, Till Uhlig, Wenche Koldingsnes, Erik Rødevand, Cecilie Kaufmann


Annals of the Rheumatic Diseases

2010